- Home
- CLPR vs DXR Comparison
CLPR vs DXR Comparison
Compare CLPR & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- DXR
- Stock Information
- Founded
- CLPR 2015
- DXR 1970
- Country
- CLPR United States
- DXR United States
- Employees
- CLPR N/A
- DXR N/A
- Industry
- CLPR Real Estate Investment Trusts
- DXR Medical/Dental Instruments
- Sector
- CLPR Real Estate
- DXR Health Care
- Exchange
- CLPR Nasdaq
- DXR Nasdaq
- Market Cap
- CLPR 57.5M
- DXR 46.9M
- IPO Year
- CLPR 2017
- DXR N/A
- Fundamental
- Price
- CLPR $3.98
- DXR $10.72
- Analyst Decision
- CLPR
- DXR Strong Buy
- Analyst Count
- CLPR 0
- DXR 1
- Target Price
- CLPR N/A
- DXR $25.00
- AVG Volume (30 Days)
- CLPR 94.9K
- DXR 78.2K
- Earning Date
- CLPR 08-07-2025
- DXR 01-01-0001
- Dividend Yield
- CLPR 9.50%
- DXR N/A
- EPS Growth
- CLPR N/A
- DXR 86.16
- EPS
- CLPR N/A
- DXR 0.11
- Revenue
- CLPR $154,103,000.00
- DXR $119,714.00
- Revenue This Year
- CLPR N/A
- DXR N/A
- Revenue Next Year
- CLPR N/A
- DXR N/A
- P/E Ratio
- CLPR N/A
- DXR $101.38
- Revenue Growth
- CLPR 7.69
- DXR N/A
- 52 Week Low
- CLPR $3.39
- DXR $6.55
- 52 Week High
- CLPR $7.12
- DXR $11.38
- Technical
- Relative Strength Index (RSI)
- CLPR 56.25
- DXR 57.46
- Support Level
- CLPR $3.55
- DXR $10.01
- Resistance Level
- CLPR $4.18
- DXR $11.02
- Average True Range (ATR)
- CLPR 0.20
- DXR 0.70
- MACD
- CLPR 0.03
- DXR 0.05
- Stochastic Oscillator
- CLPR 74.68
- DXR 67.14
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.